>> 全站文章索引 >> 第30页:
  • Drug interactions in cancer therapy - [Charity D. Scripture1 and William D. Figg1 About the authors]
  • MDMA-induced neurotoxicity: long-term effects on 5-HT biosynthesis and the influence of ambient temperature - [Esther O'shea1, Laura Orio1, Isabel Escobedo1, Veronica Sanchez1, Jorge Camarero1, Alfred Richard Green2 and Maria Isabel Colado1]
  • L-DOPA Disrupts Activity in the Nucleus Accumbens during Reversal Learning in Parkinson's Disease - [Roshan Cools1, Simon J G Lewis1, Luke Clark1, Roger A Barker2 and Trevor W Robbins1]
  • Open-label sildenafil treatment of partial and non-responders to double-blind treatment in men with antidepressant-associated sexual dysfunction - [H G Nurnberg1, M Fava2, A J Gelenberg3, P L Hensley1 and S Paine1]
  • Cognitive Dysfunction Relates to Subjective Report of Mental Fatigue in Patients with Chronic Fatigue Syndrome - [Lucile Capuron1, Leonie Welberg1, Christine Heim1, Dieter Wagner2, Laura Solomon2,4, Dimitris A Papanicolaou3,5, R Cameron Craddock2, Andrew H Miller1 and William C Reeves2]
  • Shifting emphasis from pharmacogenomics to theragnostics - [Vural Ozdemir, Bryn Williams-Jones, Stephen J Glatt, Ming T Tsuang, James B Lohr, Christopher Reist]
  • Detrimental Antidepressant Drug–Drug Interactions: Are They Clinically Relevant? - [Sheldon Preskorn1 and Steve Werder1]
  • Antidepressant–Drug Interactions are Potentially but Rarely Clinically Significant - [C Lindsay DeVane1]
  • Intrafamilial Correspondences on Platelet [3H-]Paroxetine-Binding Indices in Bulimic Probands and their Unaffected First-Degree Relatives - [Howard Steiger1,2,3, Lise Gauvin4, Ridha Joober2,3, Mimi Israel1,2,3, N M K Ng Ying Kin2,3, Kenneth R Bruce1,2,3, Jodie Richardson1,5, Simon N Young2 and Julie Hakim1]
  • Cerebrospinal Fluid Corticotropin-Releasing Factor Concentration is Associated with Pain but not Fatigue Symptoms in Patients with Fibromyalgia - [Samuel A McLean1, David A Williams2, Phyllis K Stein3, Richard E Harris2, Angela K Lyden2, Gail Whalen4, Karen M Park5, Israel Liberzon6, Ananda Sen7, Richard H Gracely2, James N Baraniuk4 and Daniel J Clauw2]
  • Clinical trial data: to disclose or not to disclose? - [Aaron Bouchie]
  • Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype - [Catherine Heurteaux, Guillaume Lucas, Nicolas Guy, Malika El Yacoubi, Susanne Th??mmler, Xiao-Dong Peng, Florence Noble, Nicolas Blondeau, Catherine Widmann, Marc Borsotto, Gabriella Gobbi, Jean-Marie Vaugeois, Guy Debonnel, Michel Lazdunski]
  • Pilot evaluation of selective serotonin reuptake inhibitor antidepressants in hot flash patients under androgen-deprivation therapy for prostate cancer - [M Naoe1, Y Ogawa1, T Shichijo1, K Fuji1, T Fukagai1 and H Yoshida1]
  • The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine - [T Sugai1, Y Suzuki1, K Sawamura1, N Fukui1, Y Inoue2 and T Someya1]
  • Temperature Regulation in Depression: Functional 5HT1A Receptor Adaptation Differentiates Antidepressant Response - [Jeffrey L Rausch1, Maria E Johnson1, Katherine E Kasik1 and Stephen M Stahl2]
  • Serotonin 2A -1438 G/A and G-Protein Beta3 Subunit C825T Polymorphisms in Patients with Depression and SSRI-Associated Sexual Side-Effects - [Jeffrey R Bishop1, Jessica Moline2, Vicki L Ellingrod2, Susan K Schultz3 and Anita H Clayton4]
  • Placebo-Controlled Trial Comparing Intermittent and Continuous Paroxetine in Premenstrual Dysphoric Disorder - [Mikael Landén1, Hans Nissbrandt2, Christer Allgulander3, Karin S?rvik4, Christina Ysander4 and Elias Eriksson2,4]
  • Permanent, Sex-Selective Effects of Prenatal or Adolescent Nicotine Exposure, Separately or Sequentially, in Rat Brain Regions: Indices of Cholinergic and Serotonergic Synaptic - [Function, Cell Signaling, and Neural Cell Number and Size at 6 Months of AgeTheodore A Slotkin1, Emiko A MacKillop1, Charles L Rudder1, Ian T Ryde1, Charlotte A Tate1 and Frederic J Seidler1]
  • Chronic Treatment with Desipramine Improves Cognitive Performance of Rats in an Attentional Set-Shifting Test - [M Danet S Lapiz1, Corina O Bondi1 and David A Morilak1]
  • Pharmacogenomic Evaluation of the Antidepressant Citalopram in the Mouse Tail Suspension Test - [James J Crowley1, Edward S Brodkin2, Julie A Blendy1, Wade H Berrettini1,2 and Irwin Lucki1,2]
  • Effect of Antidepressant Drugs in Mice Lacking the Norepinephrine Transporter - [Marta Dziedzicka-Wasylewska1, Agata Faron-Górecka1, Maciej Kumider1, Elbieta Drozdowska1, Zofia Rogó1, Joanna Siwanowicz1, Marc G Caron2 and Heinz B?nisch3]
  • Abnormal Neurotransmitter Release Underlying Behavioral and Cognitive Disorders: Toward Concepts of Dynamic and Function-Specific Dysregulation - [Martin Sarter, John P Bruno, Vinay Parikh]
  • Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors - [Centorrino, Franca, Baldessarini, Ross J, et al]
  • Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression - [Zanardi, Raffaella, Franchini, Linda, Gasperini, Mariangela, Perez, Jorge, Smeraldi, Enrico]
  • Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. - [Zajecka J, Mitchell S, Fawcett J]
  • Economic evaluation of paroxetine and imipramine in depressed outpatients. - [Melton ST, Kirkwood CK, Farrar TW, Brink DD, Carroll NV]
  • Chronic schizophrenia: Response to clozapine, risperidone, and paroxetine - [Jayendra K Patel, Carl Salzman, Alan I Green, Ming T Tsuang]
  • Acute angle closure glaucoma associated with paroxetine - [S J Benbow, G Gill]
  • Acute angle closure glaucoma associated with paroxetine - [T Eke, A K Bates, S Carr]
  • Does blinding of readers affect the results of meta-analyses? - [Jesse A Berlin]
  • Adult night terrors and paroxetine - [S J Wilson, A R Lillywhite, J P Potokar, C J Bell, D J Nutt]
  • Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. - [Richelson E]
  • Pharmacologic treatment of depression in late life - [Alastair J Flint]
  • Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. - [Piazza LA, Markowitz JC, Kocsis JH, Leon AC, Portera L, Miller NL, Adler D]
  • Efficacy studies of paroxetine in panic disorder. - [Lydiard RB, Steiner M, Burnham D, Gergel I]
  • Changes on the Temperament and Character Inventory after paroxetine treatment in volunteers with generalized anxiety disorder. - [Allgulander C, Cloninger CR, Przybeck TR, Brandt L]
  • Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. - [Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP]
  • Postural hypotension induced by paroxetine - [C Andrews, G Pinner]
  • Zebra mussel spawning is induced in low concentrations of putative serotonin reuptake inhibitors - [.]
  • Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. - [Pollock BG, Mulsant BH, Nebes R, Kirshner MA, Begley AE, Mazumdar S, Reynolds CF 3rd]
  • Rapid response of emotional incontinence to selective serotonin reuptake inhibitors - [Nahas Z, Arlinghaus KA, Kotrla KJ, Clearman RR, George MS]
  • Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial - [Bordet R, Thomas P, Dupuis B]
  • Reactions liees a l'arret du traitement aux ISRS - [Macdonald, Lynn]
  • Discontinuation reactions associated with SSRIs - [Macdonald, Lynn]
  • Antidepressants augment natural killer cell activity: in vivo and in vitro. - [Frank MG, Hendricks SE, Johnson DR, Wieseler JL, Burke WJ]
  • Bupropion (Zyban, sustained-release tablets): reported adverse reactions - [Hebert, Sylvie]
  • Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression. - [Smith GS, Reynolds CF 3rd, Pollock B, Derbyshire S, Nofzinger E, Dew MA, Houck PR, Milko D, Meltzer CC, Kupfer DJ]
  • New antidepressants for old people? - [Martin G Livingston, Hilary M Livingston]
  • Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression - [Francesco Benedetti, Alessandro Serretti, Cristina Colombo, Euridice Campori, et al]
  • Effects of paroxetine on heart period variability in patients with panic disorder: a study of holter ECG records. - [Yeragani VK, Jampala VC, Sobelewski E, Kay J, Igel G]
  • Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. - [Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L]
  • PLATELET SEROTONERGIC BINDING SITES IN ALCOHOL-DEPENDENT PATIENTS - [Belen Arranz, Pilar Rosel, Salvador Sarro, Encarna Zaldivar, Ramon Cano, Miguel Angel Navarro, Luis San]
  • Binding of [(3)H]lysergic acid diethylamide to serotonin 5-HT(2A) receptors and of [(3)H]paroxetine to serotonin uptake sites in platelets from healthy children, adolescents and adults. - [Sigurdh J, Spigset O, Allard P, Mjorndal T, Hagglof B]
  • Effect of paroxetine on thyroid hormone levels in severely depressed patients. - [Konig F, Hauger B, von Hippel, Wolfersdorf M, Kaschka WP]
  • Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. - [Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I]
  • Paroxetine in human breast milk and nursing infants. - [Stowe ZN, Cohen LS, Hostetter A, Ritchie JC, Owens MJ, Nemeroff CB]
  • Effects of Antidepressants on Weight and on the Plasma Levels of Leptin, TNF-[alpha] and Soluble TNF Receptors: A Longitudinal Study in Patients Treated with Amitriptyline or Paroxetine - [Dunja Hinze-Selch, Andreas Schuld, Thomas Kraus, Martin Kühn, Manfred Uhr, Monika Haack, Thomas Pollm?cher]
  • Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT1A receptor antagonist WAY100635 - [M S Duxon, K R Starr, N Upton]
  • Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: A fluorine MRS study - [Michael E Henry, Constance M Moore, Marc J Kaufman, David Michelson, et al]
  • The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain - [Parsey RV, Kegeles LS, Hwang DR, Simpson N, Abi-Dargham A, Mawlawi O, Slifstein M, Van Heertum RL, Mann JJ, Laruelle M]
  • Pharmacogenetics and adverse drug reactions - [Urs A Meyer]
  • The effects of antidepressants on obstructed and unobstructed gait in healthy elderly people - [Louis F Draganich, James Zacny, Jerome Klafta, Theodore Karrison]
  • The effect of paroxetine on 5-HT(2A) receptors in depression: An [18F]setoperone PET imaging study - [Jeffrey H Meyer, Shitij Kapur, Beata Eisfeld, Gregory M Brown, et al]
  • Pharmacological characterization of the serotonin transporter in young and elderly subjects. - [Marazziti D, Baroni S, Rossi A, Masala I, Giannaccini G, Gori V, Lucacchini A, Cassano GB]
  • Post-Stroke Depression, Antidepressant Treatment and Rehabilitation Results - [Stefano Paolucci, Gabriella Antonucci, Maria Grazia Grasso, Daniela Morelli, Elio Troisi, Paola Coiro, Domenico De Angelis, Francesco Rizzi, Maura Bragoni]
  • Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation - [I A Abdel-Hamid, E A El Naggar, A-H El Gilany]
  • Early Methylphenidate Administration to Young Rats Causes a Persistent Reduction in the Density of Striatal Dopamine Transporters - [Gunther H. Moll, Sharmila Hause, Eckart Rüther, Aribert Rothenberger, Gerald Huether]
  • Neonatal paroxetine withdrawal syndrome. - [Stiskal JA, Kulin N, Koren G, Ho T, Ito S]
  • Paroxetine for the prevention of depression induced by high-dose interferon alpha - [Dominique L Musselman, David H Lawson, Jane F Gumnick, Amita K Manatunga, et al]
  • Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. - [Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, Oakes R, Pitts CD]
  • Serotonin Receptor and Transporter Ligands - Current Status - [S. Oh, H-J. Ha, D. Chi, H. Lee]
  • The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain - [V Sanchez, J Camarero, B Esteban, M J Peter, A R Green, M I Colado]
  • Pindolol potentiation of paroxetine for generalized social phobia: A double-blind, placebo-controlled, crossover study - [Murray B Stein, Jitender Sareen, Shadha Hami, Jeffrey Chao.]
  • Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release - [I C Kilpatrick, M Traut, D J Heal]
  • Paroxetine approved for generalized anxiety - [Monica Preboth]
  • Understanding panic attacks - [.]
  • Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: A [11C] DASB PET imaging study - [Jeffrey H Meyer, Alan A Wilson, Nathalie Ginovart, Verdell Goulding, et al]
  • Differential effects of serotonin reuptake inhibitors on erectile responses, NO-production, and neuronal NO synthase expression in rat corpus cavernosum tissue - [Javier Angulo, Concepción Peiró, Carlos F Sanchez-Ferrer, Sonia Gabancho, Pedro Cuevas, Sandeep Gupta, I?igo Sáenz de Tejada]
  • Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters - [Carmine M Pariante, Andrew Makoff, Simon Lovestone, Susan Feroli, Alexandra Heyden, Andrew H Miller, Robert W Kerwin]
  • Have drug companies hyped social anxiety disorder to increase sales? - [David Healy, David V Sheehan]
  • Antifungal properties of selective serotonin reuptake inhibitors against Aspergillus species in vitro - [C. Lass-Florl, M. P. Dierich, D. Fuchs, E. Semenitz, I. Jenewein, M. Ledochowski]
  • Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. - [Marshall RD, Beebe KL, Oldham M, Zaninelli R]
  • Effects of chronic paroxetine administration on measures of aggressive and impulsive responses of adult males with a history of conduct disorder - [Don R. Cherek, Scott D. Lane, Cynthia J. Pietras, Joel L. Steinberg]
  • GABA(A) Receptor-Modulating Neuroactive Steroid Composition in Patients With Panic Disorder Before and During Paroxetine Treatment. - [Strohle A, Romeo E, di Michele, Pasini A, Yassouridis A, Holsboer F, Rupprecht R]
  • Depression after cardiac transplant treated with interpersonal psychotherapy and paroxetine - [Mark Miller]
  • -term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity - [Kevin C. Fone, Simon R. Beckett, Ian A. Topham, Jennifer Swettenham, Melanie Ball, Laura Maddocks]
  • Withdrawal from paroxetine can be severe, warns FDA - [Alison Tonks]
  • The selective serotonin re-uptake inhibitors fluvoxamine and paroxetine differ in sexual inhibitory effects after chronic treatment - [Marcel D. Waldinger, Afke van de Plas, Tommy Pattij, Ruud van Oorschot, Lique M. Coolen, Jan G. Veening, Berend Olivier]
  • Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex - [Frank P. Bymaster, Wei Zhang, Petra A. Carter, Janice Shaw, Eyassu Chernet, Lee Phebus, David T. Wong, Kenneth W. Perry]
  • Characterization of cocaine and antidepressant-sensitive norepinephrine transporters in rat placental trophoblasts - [Lankupalle D Jayanthi, Gricelly Vargas, Louis J DeFelice]
  • Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. - [Szabo Z, McCann UD, Wilson AA, Scheffel U, Owonikoko T, Mathews WB, Ravert HT, Hilton J, Dannals RF, Ricaurte GA]
  • Gender related disabilities in panic disorder - [G. Sachs, M. Amering, P. Berger, H. Katschnig]
  • Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. - [Yeragani VK, Roose S, Mallavarapu M, Radhakrishna RK, Pesce V]
  • High vs Low Anxiety-Related Behavior Rats: An Animal Model of Extremes in Trait Anxiety - [Rainer Landgraf, Alexandra Wigger]
  • Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. - [Gilmor ML, Owens MJ, Nemeroff CB]
  • Which selective serotonin reuptake inhibitor works best? - [Robert K Schneider, James L Levenson]
  • Panorama: The Secrets of Seroxat - [P J Cowen]
  • Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome? - [Masand PS, Gupta S, Schwartz TL, Kaplan D, Virk S, Hameed A, Lockwood K]
  • Selective Serotonin Reuptake Inhibitor Usage Patterns as Risk Factors for Hospitalization - [Reinee E. Sheffield, Anthony T. Lo Sasso, Christopher H. Young, Karen Way]
  • Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with [11C]McN 5652 - [Justine M. Kent, Jeremy D. Coplan, Ilise Lombardo, Dah-Ren Hwang, Yiyun Huang, Osama Mawlawi, Ronald L. Van Heertum,]


    • 分页: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 [30] 31 32 33 34 35 36 37 38 39 40
    41 42 43 44 45 46 47 48 49 50